Efficacy of slow-release insulin (glargine) in patients with cystic fibrosis and glucose intolerance with worsening clinical parameters.
DEC-NET Serial number IT499
Published online07/10/2005 10.26.00
Last updated10/11/2005 10.42.37
Other protocol ID number
Current trial statusOpen (actively recruiting new participants)
Major Disease
(ICD9 class)
Cystic fibrosis
Experimental drug
Insulina Glargine
GenderBoth
Age (range)> 10 years or older

Eligibility criteria
Inclusion criteria
- Cystic Fibrosis - Glucose intolerance: 2 pathologic oral glucose load curves within a 2-3 month period - At least one of the following: . BMI less than 10^th percentile for age and sex . In the last year, less of one percentile class for age and sex . FEV1 less than or egual to 80% of the abovementioned . FEV1 decrease greater than or egual to 10% in the last year.

Trial design/methodology
Phase3
Kind of studyEfficacy
Safety
DesignControlled
Randomised
Purpose of study
To improve the nutritional status of patients with Cystic Fibrosis with glucose intolerance and to improve glucose metabolic compensation and respiratory function.
Principal investigator
NameProf. Renata Lorini . Dr. Laura Minicucci
InstitutionIstituto Giannina Gaslini
Postal addressLargo G. Gaslini, 5
CityGenova
CountryITALY
Phone010 5636654
Fax
E-mailrenatalorini@ospedale-gaslini.ge.it . lauraminicucci@ospedale-gaslini.ge.it


Promoter
IRCSS - Istituto Giannina Gaslini (Scientific organisation)


Participating centres
Centro Fibrosi Cistica di Genova (Genova)
Centro Fibrosi Cistica di Bari (Bari)
Centro Fibrosi Cistica di Cerignola (Cerignola (Foggia))
Centro Fibrosi Cistica di Firenze (Firenze)
Centro Fibrosi Cistica di Messina (Messina)
Centro Fibrosi Cistica di Milano (Milano)
Centro Fibrosi Cistica di Napoli (Napoli)
Centro Fibrosi Cistica di Palermo (Palermo)
Centro Fibrosi Cistica di Parma (Parma)
Centro Fibrosi Cistica - Bambin Gesł (Roma)
Centro Fibrosi Cistica . La Sapienza (Roma)
Centro Fibrosi Cistica di Trieste (Trieste)

ISRCTN  EudraCT